tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Travere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating

Travere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating

In a report released on February 20, Joseph Schwartz from Leerink Partners maintained a Buy rating on Travere Therapeutics (TVTXResearch Report), with a price target of $42.00.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Joseph Schwartz’s rating is based on Travere Therapeutics’ strong performance and growth potential. The company reported impressive fourth-quarter sales for its product Filspari, which treats IgA nephropathy, showing a significant increase compared to the previous quarter. This growth is supported by robust patient demand, evidenced by a notable rise in patient start forms.
Furthermore, the company’s strategic approach, including anticipated regulatory advancements in treating focal segmental glomerulosclerosis (FSGS), suggests a promising future. With the potential for a market launch for FSGS treatments in the latter half of 2025, accompanied by a 75% probability of success, Schwartz sees substantial revenue opportunities. Despite the stock’s past strong performance, the analyst believes there is further potential for growth, justifying the Buy rating and maintaining a target price of $42.

In another report released on February 21, Scotiabank also reiterated a Buy rating on the stock with a $32.00 price target.

Disclaimer & DisclosureReport an Issue

1